PMID- 35481397
OWN - NLM
STAT- MEDLINE
DCOM- 20221010
LR  - 20230117
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 63
IP  - 9
DP  - 2022 Sep
TI  - African American and Caucasian patients with Sezary syndrome have no differences 
      in outcomes at an ethnically diverse urban medical center.
PG  - 2094-2101
LID - 10.1080/10428194.2022.2067999 [doi]
AB  - Sezary syndrome (SS) is an aggressive cutaneous T-cell lymphoma with poor 
      survival. We performed a retrospective review of SS patients at Emory University 
      from 1990 to 2020. We collected data on race, clinical characteristics, therapy, 
      and social determinants of health. Clinical endpoints were overall survival (OS) 
      and time to next treatment (TTNT). Univariate association and multivariable 
      analyses were assessed by Cox proportional hazards models. Among 62 patients, 
      45.2% were AA. The median OS and TTNT were 3.1 years and 6.3 months, 
      respectively, with no difference by race. AA patients had a higher median 
      baseline LDH (360 vs. 232, p = 0.002) and a longer delay in initiation of 
      systemic therapy compared to CC patients (3.17 vs. 2.14 months, p = 0.039), but a 
      shorter commute (<10 miles) and no difference in insurance coverage (p = 0.260). 
      AA patients at an academic center had unique clinical features and treatment 
      patterns, but similar survival to CC SS patients.
FAU - Martini, Dylan J
AU  - Martini DJ
AUID- ORCID: 0000-0002-0843-1222
AD  - Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
FAU - Goyal, Subir
AU  - Goyal S
AD  - Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, 
      USA.
FAU - Switchenko, Jeffrey M
AU  - Switchenko JM
AD  - Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, 
      USA.
FAU - Lechowicz, Mary Jo
AU  - Lechowicz MJ
AD  - Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.
FAU - Allen, Pamela B
AU  - Allen PB
AUID- ORCID: 0000-0002-3959-3662
AD  - Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.
LA  - eng
GR  - L30 CA242774/CA/NCI NIH HHS/United States
GR  - P30 CA138292/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220428
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Black or African American
MH  - Humans
MH  - *Mycosis Fungoides/diagnosis/epidemiology/therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Sezary Syndrome/drug therapy/therapy
MH  - *Skin Neoplasms/diagnosis/epidemiology/therapy
PMC - PMC9842406
MID - NIHMS1860259
OTO - NOTNLM
OT  - African American
OT  - Mycosis fungoides
OT  - Sezary syndrome
OT  - extracorporeal photopheresis
OT  - racial disparities
COIS- Disclosure statement DJM, SG, and JS report no conflicts, MJL reports advisory 
      board and honorarium from Kyowa Kirin, and PBA reports advisory board and 
      research funding from Kyowa Kirin.
EDAT- 2022/04/29 06:00
MHDA- 2022/10/12 06:00
PMCR- 2023/01/16
CRDT- 2022/04/28 08:32
PHST- 2022/04/29 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/04/28 08:32 [entrez]
PHST- 2023/01/16 00:00 [pmc-release]
AID - 10.1080/10428194.2022.2067999 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2022 Sep;63(9):2094-2101. doi: 10.1080/10428194.2022.2067999. Epub 
      2022 Apr 28.